Caffeine fatalities - Do sales restrictions prevent intentional intoxications?
Objective. Caffeine is widely available in beverages and in different over-the-counter products, including tablets containing 100 mg caffeine. Because intentional fatal intoxications with caffeine occur, the maximum quantity of caffeine tablets that can be bought over the counter in a single purchas...
Gespeichert in:
| Veröffentlicht in: | Clinical toxicology (Philadelphia, Pa.) Jg. 48; H. 4; S. 354 - 358 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Informa UK Ltd
01.05.2010
Taylor & Francis |
| Schlagworte: | |
| ISSN: | 1556-3650, 1556-9519, 1556-9519 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Objective. Caffeine is widely available in beverages and in different over-the-counter products, including tablets containing 100 mg caffeine. Because intentional fatal intoxications with caffeine occur, the maximum quantity of caffeine tablets that can be bought over the counter in a single purchase was restricted from 250 to 30 in Sweden in the year 2004. The objective of this article was to study the effect of this decision on the number of fatal caffeine intoxications. Method. In Sweden 95% of all cases undergoing forensic autopsy are screened for a number of drugs including caffeine. All cases during January 1993-September 2009 with a caffeine concentration above 80 μg g blood were recorded. Results. During the study period toxicological investigations were performed in 83,580 forensic autopsies. Caffeine contributed to the fatal outcome in 20 cases (0.02%). Thirteen (65%) of these fatalities occurred before the introduction of the sales restriction. However, no fatal intoxications where caffeine contributed to the cause of death was recorded between May 2007 and September 2009. Conclusion. Overdoses of tablets containing caffeine can be fatal, suicides as well as accidents occur. Restricting the maximum quantity of caffeine tablets available over the counter seemed to be effective in preventing suicides because of caffeine although some time elapsed until the effect was noted. Further monitoring is required to ensure that the observed lower caffeine mortality is a sustained effect. |
|---|---|
| AbstractList | Caffeine is widely available in beverages and in different over-the-counter products, including tablets containing 100 mg caffeine. Because intentional fatal intoxications with caffeine occur, the maximum quantity of caffeine tablets that can be bought over the counter in a single purchase was restricted from 250 to 30 in Sweden in the year 2004. The objective of this article was to study the effect of this decision on the number of fatal caffeine intoxications.
In Sweden 95% of all cases undergoing forensic autopsy are screened for a number of drugs including caffeine. All cases during January 1993-September 2009 with a caffeine concentration above 80 microg/g blood were recorded.
During the study period toxicological investigations were performed in 83,580 forensic autopsies. Caffeine contributed to the fatal outcome in 20 cases (0.02%). Thirteen (65%) of these fatalities occurred before the introduction of the sales restriction. However, no fatal intoxications where caffeine contributed to the cause of death was recorded between May 2007 and September 2009.
Overdoses of tablets containing caffeine can be fatal, suicides as well as accidents occur. Restricting the maximum quantity of caffeine tablets available over the counter seemed to be effective in preventing suicides because of caffeine although some time elapsed until the effect was noted. Further monitoring is required to ensure that the observed lower caffeine mortality is a sustained effect. Objective. Caffeine is widely available in beverages and in different over-the-counter products, including tablets containing 100 mg caffeine. Because intentional fatal intoxications with caffeine occur, the maximum quantity of caffeine tablets that can be bought over the counter in a single purchase was restricted from 250 to 30 in Sweden in the year 2004. The objective of this article was to study the effect of this decision on the number of fatal caffeine intoxications. Method. In Sweden 95% of all cases undergoing forensic autopsy are screened for a number of drugs including caffeine. All cases during January 1993-September 2009 with a caffeine concentration above 80 μg/g blood were recorded. Results. During the study period toxicological investigations were performed in 83,580 forensic autopsies. Caffeine contributed to the fatal outcome in 20 cases (0.02%). Thirteen (65%) of these fatalities occurred before the introduction of the sales restriction. However, no fatal intoxications where caffeine contributed to the cause of death was recorded between May 2007 and September 2009. Conclusion. Overdoses of tablets containing caffeine can be fatal, suicides as well as accidents occur. Restricting the maximum quantity of caffeine tablets available over the counter seemed to be effective in preventing suicides because of caffeine although some time elapsed until the effect was noted. Further monitoring is required to ensure that the observed lower caffeine mortality is a sustained effect. Caffeine is widely available in beverages and in different over-the-counter products, including tablets containing 100 mg caffeine. Because intentional fatal intoxications with caffeine occur, the maximum quantity of caffeine tablets that can be bought over the counter in a single purchase was restricted from 250 to 30 in Sweden in the year 2004. The objective of this article was to study the effect of this decision on the number of fatal caffeine intoxications.OBJECTIVECaffeine is widely available in beverages and in different over-the-counter products, including tablets containing 100 mg caffeine. Because intentional fatal intoxications with caffeine occur, the maximum quantity of caffeine tablets that can be bought over the counter in a single purchase was restricted from 250 to 30 in Sweden in the year 2004. The objective of this article was to study the effect of this decision on the number of fatal caffeine intoxications.In Sweden 95% of all cases undergoing forensic autopsy are screened for a number of drugs including caffeine. All cases during January 1993-September 2009 with a caffeine concentration above 80 microg/g blood were recorded.METHODIn Sweden 95% of all cases undergoing forensic autopsy are screened for a number of drugs including caffeine. All cases during January 1993-September 2009 with a caffeine concentration above 80 microg/g blood were recorded.During the study period toxicological investigations were performed in 83,580 forensic autopsies. Caffeine contributed to the fatal outcome in 20 cases (0.02%). Thirteen (65%) of these fatalities occurred before the introduction of the sales restriction. However, no fatal intoxications where caffeine contributed to the cause of death was recorded between May 2007 and September 2009.RESULTSDuring the study period toxicological investigations were performed in 83,580 forensic autopsies. Caffeine contributed to the fatal outcome in 20 cases (0.02%). Thirteen (65%) of these fatalities occurred before the introduction of the sales restriction. However, no fatal intoxications where caffeine contributed to the cause of death was recorded between May 2007 and September 2009.Overdoses of tablets containing caffeine can be fatal, suicides as well as accidents occur. Restricting the maximum quantity of caffeine tablets available over the counter seemed to be effective in preventing suicides because of caffeine although some time elapsed until the effect was noted. Further monitoring is required to ensure that the observed lower caffeine mortality is a sustained effect.CONCLUSIONOverdoses of tablets containing caffeine can be fatal, suicides as well as accidents occur. Restricting the maximum quantity of caffeine tablets available over the counter seemed to be effective in preventing suicides because of caffeine although some time elapsed until the effect was noted. Further monitoring is required to ensure that the observed lower caffeine mortality is a sustained effect. Objective. Caffeine is widely available in beverages and in different over-the-counter products, including tablets containing 100 mg caffeine. Because intentional fatal intoxications with caffeine occur, the maximum quantity of caffeine tablets that can be bought over the counter in a single purchase was restricted from 250 to 30 in Sweden in the year 2004. The objective of this article was to study the effect of this decision on the number of fatal caffeine intoxications. Method. In Sweden 95% of all cases undergoing forensic autopsy are screened for a number of drugs including caffeine. All cases during January 1993-September 2009 with a caffeine concentration above 80 mu g/g blood were recorded. Results. During the study period toxicological investigations were performed in 83,580 forensic autopsies. Caffeine contributed to the fatal outcome in 20 cases (0.02%). Thirteen (65%) of these fatalities occurred before the introduction of the sales restriction. However, no fatal intoxications where caffeine contributed to the cause of death was recorded between May 2007 and September 2009. Conclusion. Overdoses of tablets containing caffeine can be fatal, suicides as well as accidents occur. Restricting the maximum quantity of caffeine tablets available over the counter seemed to be effective in preventing suicides because of caffeine although some time elapsed until the effect was noted. Further monitoring is required to ensure that the observed lower caffeine mortality is a sustained effect. |
| Author | Forsberg, Gunilla Sjölin Lundqvist, Kristina Magnusson Thelander, Gunilla Ahlner, Johan Personne, Mark Jönsson, Anna Kristina |
| Author_xml | – sequence: 1 givenname: Gunilla surname: Thelander fullname: Thelander, Gunilla email: johan.ahlner@rmv.se, johan.ahlner@rmv.se organization: 1Department of Forensic Genetics and Forensic Toxicology, The National Board of Forensic Medicine, Linköping, Sweden – sequence: 2 givenname: Anna Kristina surname: Jönsson fullname: Jönsson, Anna Kristina email: johan.ahlner@rmv.se, johan.ahlner@rmv.se organization: 1Department of Forensic Genetics and Forensic Toxicology, The National Board of Forensic Medicine, Linköping, Sweden – sequence: 3 givenname: Mark surname: Personne fullname: Personne, Mark email: johan.ahlner@rmv.se, johan.ahlner@rmv.se organization: 1Department of Forensic Genetics and Forensic Toxicology, The National Board of Forensic Medicine, Linköping, Sweden – sequence: 4 givenname: Gunilla Sjölin surname: Forsberg fullname: Forsberg, Gunilla Sjölin email: johan.ahlner@rmv.se, johan.ahlner@rmv.se organization: 1Department of Forensic Genetics and Forensic Toxicology, The National Board of Forensic Medicine, Linköping, Sweden – sequence: 5 givenname: Kristina Magnusson surname: Lundqvist fullname: Lundqvist, Kristina Magnusson email: johan.ahlner@rmv.se, johan.ahlner@rmv.se organization: 1Department of Forensic Genetics and Forensic Toxicology, The National Board of Forensic Medicine, Linköping, Sweden – sequence: 6 givenname: Johan surname: Ahlner fullname: Ahlner, Johan email: johan.ahlner@rmv.se, johan.ahlner@rmv.se organization: 1Department of Forensic Genetics and Forensic Toxicology, The National Board of Forensic Medicine, Linköping, Sweden |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20170393$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-58332$$DView record from Swedish Publication Index (Linköpings universitet) |
| BookMark | eNp9kU1v1DAQhq2qqF_0B_SCcuNCwI7j2FGRULXlS6rgAlytWWdCXXntre1Q-u9xulukFtHTvBo9z1jjOSS7Pngk5ITR15zR_g0TouOdoD3lQnVSNDvkYO7VvWD97jbPwD45TOmKUq7anu2R_YYySXnPD8iXBYwjWo_VCBmczRZTVVfnoUrgSoyYcrQm2-BTtY74C32urM-llBa4OYff1sAd8e45eTaCS3i8rUfk-4f33xaf6ouvHz8vzi5q07ZNrhVSlEvJJR86AKASS25awB6pGJoOBQMOLfQSqAIclq1QCrpWyZGqoTP8iLzazE03uJ6Weh3tCuKtDmD1uf1xpkP8qZ2dtFCcNwV_ucHXMVxPZSW9ssmgc-AxTElLzhmjjWwL-WJLTssVDn8H3_9YAeQGMDGkFHHUxua77XME6zSjer6N_uc2xWSPzPvhTzlvN471Y4gruAnRDTrDrQtxjOCNTbP6f_30gX6J4PKlgYj6Kkyx3C898fgfqLK1jA |
| CitedBy_id | crossref_primary_10_1093_jat_bkx011 crossref_primary_10_1186_s12889_018_5178_2 crossref_primary_10_1001_jamahealthforum_2021_3042 crossref_primary_10_1016_j_jad_2019_06_023 crossref_primary_10_1016_j_legalmed_2025_102680 crossref_primary_10_1016_j_scitotenv_2021_148440 crossref_primary_10_1080_19390211_2017_1356418 crossref_primary_10_1089_jcr_2011_1204 crossref_primary_10_1016_j_ijcard_2015_11_118 crossref_primary_10_1016_j_toxlet_2017_10_019 crossref_primary_10_1016_j_fct_2022_113082 crossref_primary_10_3390_nu10050611 crossref_primary_10_1016_j_taap_2018_01_008 crossref_primary_10_1016_j_forsciint_2011_02_028 crossref_primary_10_1016_j_hrthm_2024_02_018 crossref_primary_10_12793_tcp_2017_25_3_141 crossref_primary_10_1002_dta_1485 crossref_primary_10_1007_s13181_025_01057_w crossref_primary_10_1080_19440049_2014_940608 crossref_primary_10_1089_jcr_2013_1226 crossref_primary_10_1016_j_taap_2015_09_007 crossref_primary_10_1016_S2215_0366_16_30030_X crossref_primary_10_1007_s12024_014_9571_6 crossref_primary_10_1016_j_tox_2019_02_008 crossref_primary_10_1016_j_ecoenv_2023_115797 crossref_primary_10_1002_tox_23630 crossref_primary_10_1016_j_yrtph_2018_05_008 crossref_primary_10_1186_s12882_024_03905_3 crossref_primary_10_1016_j_ajem_2021_03_017 crossref_primary_10_14814_phy2_13632 crossref_primary_10_1155_2015_537689 crossref_primary_10_1016_j_ejpb_2021_01_017 crossref_primary_10_1016_j_fct_2017_04_002 crossref_primary_10_1007_s40596_019_01096_w crossref_primary_10_1016_j_fct_2015_01_022 crossref_primary_10_1038_srep17746 crossref_primary_10_1155_2017_4061205 crossref_primary_10_1016_j_reprotox_2017_06_045 crossref_primary_10_1016_j_vascn_2020_106946 crossref_primary_10_1016_j_jfutfo_2025_03_011 crossref_primary_10_1007_s00431_015_2581_x crossref_primary_10_1016_j_cbpc_2014_03_004 crossref_primary_10_1016_j_toxlet_2025_06_007 crossref_primary_10_1016_j_taap_2015_03_002 crossref_primary_10_1080_07315724_2014_907756 |
| Cites_doi | 10.1016/S0031-6997(24)01396-6 10.2165/00002018-200730060-00002 10.2131/jts.32.1 10.1002/j.1552-4604.1997.tb04356.x 10.1016/j.forsciint.2005.04.016 10.2165/00003088-200039020-00004 10.1111/j.1365-2125.2008.03206.x 10.1016/0379-0738(85)90114-8 10.1111/j.1365-2125.2006.02668.x 10.5694/j.1326-5377.2001.tb143404.x 10.1093/jat/9.3.141 10.1258/rsmsmj.54.4.3 10.1520/JFS14071J 10.1016/j.ajem.2007.10.018 10.1016/j.forsciint.2003.09.019 10.1081/CLT-100102405 10.1111/j.1365-2044.2005.04430.x |
| ContentType | Journal Article |
| Copyright | Informa UK, Ltd. 2010 |
| Copyright_xml | – notice: Informa UK, Ltd. 2010 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS DG8 |
| DOI | 10.3109/15563650903586752 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic SwePub SwePub Articles SWEPUB Linköpings universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health Medicine |
| EISSN | 1556-9519 |
| EndPage | 358 |
| ExternalDocumentID | oai_DiVA_org_liu_58332 20170393 10_3109_15563650903586752 459184 |
| Genre | Research Article Journal Article |
| GeographicLocations | Sweden |
| GeographicLocations_xml | – name: Sweden |
| GroupedDBID | --- .GJ 00X 03L 0BK 0R~ 29B 34G 36B 39C 3O- 4.4 53G 5RE 5VS AAJNR AALIY AALUX AAMIU AAPUL AAQRR ABBKH ABCRQ ABDBF ABEIZ ABLKL ABPTK ABUPF ACENM ACFUF ACGFS ACLSK ADCVX ADFCX ADRBQ AECIN AENEX AEOZL AEYQI AFKVX AFWLO AGAFX AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AJEBJ AJWEG AKBVH ALIIL ALMA_UNASSIGNED_HOLDINGS ALQZU AWYRJ BABNJ BLEHA BOHLJ CAG CCCUG COF DEIEU DKSSO DTRLO DU5 DZHFC EAP EAS EBC EBD EBS EDH EHN EJD EMB EMK EMOBN EPL EPT ESX F5P H13 HZ~ J.N KRBQP KSSTO KWAYT KYCEM LJTGL LSO M44 M4Z O9- QRXOQ Q~Q RNANH RVRKI SV3 TFDNU TFL TFW TUS UHWXJ V1S ~1N AAGDL ABJNI ABLIJ ABWVI ABXYU ACIEZ ACUHS AFRVT AHZWE ALYBC AQTUD TASJS TBQAZ TDBHL TERGH TUROJ AARSK AAYXX ACKYO BANNL CITATION NUSFT RIG ADYSH CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS DG8 |
| ID | FETCH-LOGICAL-c442t-8e0e7b7373d6aaa07e73724ae9e05d26e51a3a4a97a08aedb4588a6487f08d6c3 |
| IEDL.DBID | TFW |
| ISICitedReferencesCount | 57 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000279057000007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1556-3650 1556-9519 |
| IngestDate | Tue Nov 04 17:05:58 EST 2025 Fri Sep 05 13:03:41 EDT 2025 Thu Apr 03 07:01:54 EDT 2025 Sat Nov 29 08:18:18 EST 2025 Tue Nov 18 22:19:02 EST 2025 Mon Oct 20 23:45:10 EDT 2025 Wed Jun 21 01:44:17 EDT 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Toxicology Poisoning Fatal Caffeine |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c442t-8e0e7b7373d6aaa07e73724ae9e05d26e51a3a4a97a08aedb4588a6487f08d6c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 20170393 |
| PQID | 733110274 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | informahealthcare_journals_10_3109_15563650903586752 swepub_primary_oai_DiVA_org_liu_58332 informaworld_taylorfrancis_310_3109_15563650903586752 proquest_miscellaneous_733110274 crossref_citationtrail_10_3109_15563650903586752 crossref_primary_10_3109_15563650903586752 pubmed_primary_20170393 |
| PublicationCentury | 2000 |
| PublicationDate | 2010-05-01 |
| PublicationDateYYYYMMDD | 2010-05-01 |
| PublicationDate_xml | – month: 05 year: 2010 text: 2010-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Clinical toxicology (Philadelphia, Pa.) |
| PublicationTitleAlternate | Clin Toxicol (Phila) |
| PublicationYear | 2010 |
| Publisher | Informa UK Ltd Taylor & Francis |
| Publisher_xml | – name: Informa UK Ltd – name: Taylor & Francis |
| References | Hedetoft C (CIT0007) 1999; 161 CIT0010 CIT0021 CIT0020 CIT0011 Sweetman SC (CIT0017) 2009 CIT0022 Kanstrup MH (CIT0009) 2003; 165 Hardman JG (CIT0001) 2006 Cannon ME (CIT0008) 2001; 174 Fredholm BB (CIT0012) 1999; 51 Mrvos RM (CIT0006) 1989; 31 CIT0003 CIT0014 CIT0002 CIT0013 CIT0005 CIT0016 CIT0004 CIT0015 CIT0018 CIT0019 |
| References_xml | – volume: 51 start-page: 83 year: 1999 ident: CIT0012 publication-title: Pharmacol Rev doi: 10.1016/S0031-6997(24)01396-6 – volume: 165 start-page: 239 year: 2003 ident: CIT0009 publication-title: Ugeskr Laeger – ident: CIT0021 doi: 10.2165/00002018-200730060-00002 – volume: 31 start-page: 571 year: 1989 ident: CIT0006 publication-title: Vet Hum Toxicol – ident: CIT0018 doi: 10.2131/jts.32.1 – volume-title: Goodman and Gilman’s The Pharmacological Basis of Therapeutics year: 2006 ident: CIT0001 – volume: 161 start-page: 6937 year: 1999 ident: CIT0007 publication-title: Ugeskr Laeger – ident: CIT0022 doi: 10.1002/j.1552-4604.1997.tb04356.x – ident: CIT0011 doi: 10.1016/j.forsciint.2005.04.016 – ident: CIT0016 doi: 10.2165/00003088-200039020-00004 – ident: CIT0019 doi: 10.1111/j.1365-2125.2008.03206.x – ident: CIT0005 doi: 10.1016/0379-0738(85)90114-8 – volume-title: Martindale – The Complete Drug Reference year: 2009 ident: CIT0017 – ident: CIT0020 doi: 10.1111/j.1365-2125.2006.02668.x – volume: 174 start-page: 520 year: 2001 ident: CIT0008 publication-title: Med J Aust doi: 10.5694/j.1326-5377.2001.tb143404.x – ident: CIT0004 doi: 10.1093/jat/9.3.141 – ident: CIT0002 doi: 10.1258/rsmsmj.54.4.3 – ident: CIT0015 doi: 10.1520/JFS14071J – ident: CIT0003 doi: 10.1016/j.ajem.2007.10.018 – ident: CIT0010 doi: 10.1016/j.forsciint.2003.09.019 – ident: CIT0014 doi: 10.1081/CLT-100102405 – ident: CIT0013 doi: 10.1111/j.1365-2044.2005.04430.x |
| SSID | ssj0038491 |
| Score | 2.1675303 |
| Snippet | Objective. Caffeine is widely available in beverages and in different over-the-counter products, including tablets containing 100 mg caffeine. Because... Caffeine is widely available in beverages and in different over-the-counter products, including tablets containing 100 mg caffeine. Because intentional fatal... |
| SourceID | swepub proquest pubmed crossref informaworld informahealthcare |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 354 |
| SubjectTerms | Adolescent Adult Aged Aged, 80 and over Caffeine Caffeine - blood Caffeine - economics Caffeine - poisoning Central Nervous System Stimulants - economics Central Nervous System Stimulants - poisoning Commerce - legislation & jurisprudence Drug Overdose - mortality Drug Overdose - prevention & control Fatal Female Humans Male MEDICIN MEDICINE Middle Aged Poisoning Substance-Related Disorders - mortality Suicide - prevention & control Suicide - statistics & numerical data Sweden - epidemiology Toxicology Young Adult |
| Title | Caffeine fatalities - Do sales restrictions prevent intentional intoxications? |
| URI | https://www.tandfonline.com/doi/abs/10.3109/15563650903586752 https://www.ncbi.nlm.nih.gov/pubmed/20170393 https://www.proquest.com/docview/733110274 https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-58332 |
| Volume | 48 |
| WOSCitedRecordID | wos000279057000007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 1556-9519 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0038491 issn: 1556-9519 databaseCode: TFW dateStart: 20050101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBZp6KFQmvS9aRt0aC8FUXv19CmEpEsOYckhbfcmxvaoXQjrsN4t-fnRWPaSJmkO7c1gj5ClGY00mvk-xj6q3AWIjkJgYbRQElBA5UDUAXOwpcE8gSSd2unUzWbFWZ-b0_ZplXSGDgkoolurybih7BhICMfyS06gVoT8lknt4oaXVuDo9om_4HzyY1iHpVNFQkvVRtDn6U7z_hb-8Eq7PWbpr00G1i0c0_t2o7egRjv3NNn5zx_bZc_6fSk_TIr0nG3h4gV7moJ6PNUqvWTTIwgBY7s8UNSnA2Plgh83vI1-puXE87Gcd5USLb9M4FCcACn6tHZ6bq6GKOHBK_Zt8vX86ET0hAyiUmq8Eg4ztKWVVtYGADKLRHKjAAvMdD02qHOQoKCwkDnAuqQyWDDxTBQyV5tKvmbbi2aBbxnXBos65FhqA8RyDpVWFl0dtKtUXFVGLBsmxFc9WjmRZlz4eGqhwfJ3BmvEPm9ELhNUx0Mfqzuz7HvzbR8S0zcVwa-6sEpIHCgk81c5PmiMj_ZLlzKwwGbdeuLMzCk2MGJvkiZtOj8mbCNZyBH7lFRr84YwwY_n3w99s_zpL-ZrT7Vz471_7Nw79mTIicjy92x7tVzjB_a4-r2at8t99sjO3H5nWtdPlR20 |
| linkProvider | Taylor & Francis |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQQQIJQXlvKeADXJCsOutHnFNVtayKWFYcFujNmk3GZaVqU212ET8fT5ys6IMe4BYpGcux5-EZz3zD2FuduQDRUAgsrBFaAQooHYgqYAb5zGKWQJLG-WTiTk6KL13ArenSKsmHDgkootXVJNwUjN5rXUxZ7GWEakXQb1IZF0-8UQXfNtHOEodPR997TaycLhJeqrGCvk-3mtcPccEubXeopT82OViXkEyvO49eAhttDdTo4f_-2jZ70B1N-UHipUfsFi4es_sprsdTudITNjmEEDAOzAMFflo8Vi74Uc2baGoaTq0-lvO2WKLh5wkfihMmRZfZTs_1rz5QuP-UfR19mB4ei64ngyi1Hq6EQ4n5LFe5qiwAyBypz40GLFCaamjRZKBAQ5GDdIDVjCphwUa3KEhX2VI9Y1uLeoEvGDcWiypkODMWqNE5lEbn6KpgXKmjYhkw2e-ILzvAcuqbceaj40KL5a8s1oC935CcJ7SOmz7WV7bZdxLc3ERm_uQEv2ojKyG1QSGav9LxnmV8FGG6l4EF1uvGU9vMjMIDA_Y8sdJm8kOCN1KFGrB3ibc2bwgW_Gj-7cDXy1N_Nl97Kp8b7vzj5N6wu8fTz2M__jj59JLd61MkZLbLtlbLNb5id8qfq3mzfN1K2G-eNyD3 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBYlLaVQ0vS9ferQXgoi8uph-VRCNktLw5JD2uYmZu1RuxDWy3o35OdHY9lLm6Q5pDeDPUKW5qEZzXzD2AeduQDRUAgsrBFaAQooHYgqYAb51GKWQJIO88nEnZwUR11uTtOlVZIPHRJQRKurSbgXVdhtPUxZ7GYEakXIb1IZFw-8UQPfjcdmS77X8fhnr4iV00WCSzVW0PfpUvP6If4ySzsdaOnvTQrWJSDT646jl7BGW_s0fvSff7bDtruDKd9LnPSY3cH5E_YwRfV4KlZ6yib7EALGcXmgsE-LxsoFH9W8iYam4dToYzlrSyUavkjoUJwQKbq8dnquz_sw4edn7Pv44Hj_i-g6MohS6-FKOJSYT3OVq8oCgMyRutxowAKlqYYWTQYKNBQ5SAdYTakOFmx0ioJ0lS3Vc7Y1r-f4knFjsahChlNjgdqcQ2l0jq4KxpU6qpUBk_2G-LKDK6euGac-ui20WP7KYg3Ypw3JImF13PSxvrLLvpPf5iYy8ycj-FUbVwmpCQrR_JOO9xzjowDTrQzMsV43nppmZhQcGLAXiZM2kx8SuJEq1IB9TKy1eUOg4KPZjz1fL3_509naU_Hc8NUtJ_ee3T8ajf3h18m31-xBnx8hszdsa7Vc41t2rzxbzZrlu1a-LgAXHh-o |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Caffeine+fatalities+-+Do+sales+restrictions+prevent+intentional+intoxications%3F&rft.jtitle=Clinical+toxicology+%28Philadelphia%2C+Pa.%29&rft.au=Thelander%2C+Gunilla&rft.au=J%C3%B6nsson%2C+Anna+Kristina&rft.au=Personne%2C+Mark&rft.au=Forsberg%2C+Gunilla+Sj%C3%B6lin&rft.date=2010-05-01&rft.pub=Taylor+%26+Francis&rft.issn=1556-3650&rft.eissn=1556-9519&rft.volume=48&rft.issue=4&rft.spage=354&rft.epage=358&rft_id=info:doi/10.3109%2F15563650903586752&rft.externalDocID=459184 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1556-3650&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1556-3650&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1556-3650&client=summon |